Author

Kai C. Johnson

Observed names: Kai C C Johnson, Kai CC Johnson

Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University

Observed institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University

ORCID: 0000-0002-5779-4732

Observed ORCID: 0000-0002-5779-4732

OpenAlex ID: A5132884558

Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer – a review of current evidence for and against the use of anti-HER2 treatment regimens

2022 · Kai CC Johnson, Dionisia Quiroga, et al. · Expert Review of Anticancer Therapy · 4

Radiation Management After Neoadjuvant Therapy in Breast Cancer: Current Evidence and Evolving Paradigms

2026 · Tugce Kutuk, Marshall Harrell, et al. · Current Breast Cancer Reports

Effect of tango versus exercise on chemotherapy-induced neuropathy after breast cancer treatment: a Phase II randomized controlled trial

2026 · Lise Worthen-Chaudhari, Patrick Schnell, et al. · Research Square

Impact of Oncotype DX risk categorization and receipt of chemotherapy on survival outcomes among patients with small node-negative HR+ breast cancer

2026 · Andrea House, Julie A Stephens, et al. · The Oncologist

Management of bone metastases in patients with breast cancer: review of bone-modifying therapy, emerging new agents, and future directions

2026 · Gilbert Bader, Brianna Brown, et al. · Frontiers in Oncology

Denosumab as Second-Line Treatment in Patients With Metastatic Breast Cancer: A Retrospective Descriptive Pilot Study From a Single Institution

2026 · Briana To, Laura E. Wright, et al. · Cancer Control

Abstract 6645: Practice patterns impacting relative dose intensity of adjuvant capecitabine among triple negative breast cancer patients with residual disease following neoadjuvant chemotherapy.

2026 · Andrea House, Pratik Thakur, et al. · Cancer Research

Abstract 6646: Impact of histology subtypes (ductal, lobular, and mixed ductal/lobular) on pathological complete response (pCR) following neoadjuvant chemotherapy (NAC) and chemoimmunotherapy (NACI) for estrogen receptor low (ER-low) HER2-negative breast cancer.

2026 · Kai C. Johnson, Brandon Slover, et al. · Cancer Research

Author response for "Denosumab as Second-line Treatment in patients with metastatic breast cancer: A retrospective descriptive pilot study from a single institution"

2026 · Briana To, Laura E. Wright, et al.

Author response for "Denosumab as Second-line Treatment in patients with metastatic breast cancer: A retrospective descriptive pilot study from a single institution"

2025 · Briana To, Laura E. Wright, et al.

Works count: 10

Citation count: 4

H-index: 1

I10-index: